Courtenay-Luck N - Search Results

1

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. Walter HS, et al. Among authors: courtenay luck n. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5. Blood. 2016. PMID: 26542378 Free PMC article. Clinical Trial.

2

Targeting of monoclonal antibodies to tumours.

Courtenay-Luck NS, Epenetos AA. Courtenay-Luck NS, et al. Curr Opin Immunol. 1989-1990;2(6):880-3. doi: 10.1016/0952-7915(89)90172-6. Curr Opin Immunol. 1989. PMID: 2486568 Review. No abstract available.

3

Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.

Kosmas C, Epenetos AA, Courtenay-Luck NS. Kosmas C, et al. Br J Cancer. 1991 Sep;64(3):494-500. doi: 10.1038/bjc.1991.337. Br J Cancer. 1991. PMID: 1911190 Free PMC article.

4

Immunolocalisation of testicular tumours using radiolabelled monoclonal antibody to placental alkaline phosphatase.

Kalofonos HP, Kosmas C, Pawlikowska TR, Bamias A, Snook D, Dhokia B, Sivolapenko GB, Courtenay-Luck NS, Epenetos AA. Kalofonos HP, et al. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4):294-8. J Nucl Med Allied Sci. 1990. PMID: 2090793

5

Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies.

Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larche M, Barkans JR, Ritter MA. Courtenay-Luck NS, et al. Lancet. 1988 Oct 15;2(8616):894-7. doi: 10.1016/s0140-6736(88)92482-8. Lancet. 1988. PMID: 2902328 Clinical Trial.

6

Generation of monoclonal antibodies utilizing the host anti-idiotypic network.

Hatzistilianou MN, Sivolapenko GB, Courtenay-Luck NS, Epenetos AA, Ritter MA. Hatzistilianou MN, et al. In Vivo. 1995 Mar-Apr;9(2):139-44. In Vivo. 1995. PMID: 7548789

7

Antibody-guided irradiation of hepatic metastases using intrahepatically administered radiolabelled anti-CEA antibodies with simultaneous and reversible hepatic blood flow stasis using biodegradable starch microspheres.

Epenetos AA, Courtenay-Luck N, Dhokia B, Snook D, Hooker G, Lavender JP, Hemmingway A, Carr D, Paraharalambous M, Bosslet K. Epenetos AA, et al. Nucl Med Commun. 1987 Dec;8(12):1047-58. doi: 10.1097/00006231-198712000-00014. Nucl Med Commun. 1987. PMID: 3449789

8

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1.

Pericleous LM, Richards J, Epenetos AA, Courtenay-Luck N, Deonarain MP. Pericleous LM, et al. Among authors: courtenay luck n. Br J Cancer. 2005 Nov 28;93(11):1257-66. doi: 10.1038/sj.bjc.6602847. Br J Cancer. 2005. PMID: 16265351 Free PMC article.

9

Intraperitoneal administration of an I125 labelled monoclonal antibody for localization of human colorectal cancer in the nude mouse.

Shihab F, Azar HA, Finney R, Tyson IB, Tenorio LE, Courtenay-Luck N, Epenetos AA, Hadden JW. Shihab F, et al. Int J Immunopharmacol. 1987;9(7):783-92. doi: 10.1016/0192-0561(87)90074-9. Int J Immunopharmacol. 1987. PMID: 2828253

10

Effects of phorbol esters and cytokines (interleukin-2,-4, and -6) on the proliferation and surface phenotype of Epstein-Barr virus immortalised human B lymphocytes.

Kosmas C, Epenetos AA, Courtenay-Luck NS. Kosmas C, et al. Leuk Lymphoma. 1992 Sep;8(1-2):109-15. doi: 10.3109/10428199209049824. Leuk Lymphoma. 1992. PMID: 1337296

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page